I read a post on the other site that states any partner will want to see final results before entering into any deal and that this is at least 60 days away. That is certainly entirely possible, just as it is possible that the data will not be compelling enough to cause any interest in any partnership/buyout/etc. It is also possible that one of the CNDA companies (the more of them there are the more likely this could be) that may be crunching data at this time will reach the conclusion that this drug/company is likely to be very valuable and may want to put forth an aggressive offer to get in ahead of competing companies. Could happen today, might be after final data, and might never happen. These same CNDA companies are almost certainly aware of any interest by the others and all are certainly aware of both Prurisol and Kevetrin. What offer would they make? What offer would be accepted by CEO/Board? Be in or be out.
I read a post on the other site that states any partner
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Experience Culinary Excellence at Hong Kong Wine & Dine Festival
Hong Kong Wine & Dine Festival Returns This October HONG KONG, an anticipated gastronomic spectacle is set for the latter part of October. The Hong Kong Wine & Dine Festival will take place from 23 to 26 October 2025 at the iconic Central Harbourfront. This annual celebration is designed to showcase the best in culinary arts and exquisite wines, offering something special...
Continue Reading
Danaher Announces Upcoming Earnings Conference Details
Danaher Sets Date for Q3 2024 Earnings Conference Call Danaher Corporation (NYSE: DHR) has announced the date for its highly anticipated quarterly earnings conference call. This event is significant for investors and stakeholders who keep a close eye on the company's developments. Earnings Call Details The earnings call is set for an upcoming Tuesday morning, during which...
Continue Reading
UniQure's Stock Climbs to Record Levels, Eyes Future Growth
UniQure Stock Reaches New Heights UniQure NV (QURE) has exciting news as its stock recently touched an impressive 52-week high of $18.5. This remarkable milestone is a testament to the company's resilient growth strategy and innovative advancements in the biotechnology industry. With a market capitalization reaching $885 million, the stock has seen an astonishing rise of...
Continue Reading
MedCana's Colombian Subsidiary Partners with Australian Firm
MedCana Enters Negotiations for Cannabis Supply Agreement MedCana, a prominent player in the pharmaceutical-grade cannabis landscape, is making headlines with an exciting new development from its subsidiary in Colombia. The company is set to negotiate a substantial supply agreement worth between $1.2 million and $2.4 million annually. This agreement marks a significant...
Continue Reading
Mouawad and OCTA Properties Launch Luxurious Residences
Mouawad Teams Up with OCTA Properties for Luxe Residences OCTA Properties has been selected as the global licensee for residences branded by Mouawad, bringing the brand's legacy of timeless elegance into the realm of premium real estate. This partnership marks an exciting new chapter in Mouawad's prestigious journey in luxury development. A Landmark Collaboration Mouawad,...
Continue Reading